Few drug classes in modern medicine have crossed into genuine cultural relevance. Statins reshaped cardiology. SSRIs redefined psychiatry. Penicillin changed surgery. GLP-1 receptor agonists — semaglutide, tirzepatide, and the generation that follows — appear to belong in that company. What started as a niche tool for managing blood sugar in Type 2 diabetes became a global weight-loss phenomenon between 2022 and 2024. What emerged from the clinical trial data accumulated since then is something considerably more interesting.
These drugs are not simply making people thinner. They appear to be altering the way the brain processes reward, craving, and inflammation. The implications reach well beyond the bathroom scale.
What GLP-1 Receptors Actually Do
Glucagon-like peptide-1 is a hormone produced naturally in the gut after eating. Its primary function is to stimulate insulin secretion in response to rising blood glucose — a mechanism called glucose-dependent insulinotropic regulation. Critically, GLP-1 also signals to the hypothalamus to suppress appetite and slow gastric emptying, producing a sensation of fullness that persists longer than the meal warrants.
Pharmaceutical GLP-1 receptor agonists — drugs engineered to mimic or amplify this signal — have a much longer half-life than the natural hormone. Native GLP-1 degrades in about two minutes. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight management) has a half-life of approximately seven days, allowing for once-weekly injection. Tirzepatide (Mounjaro, Zepbound) goes further, targeting both GLP-1 and GIP receptors simultaneously — a dual agonism that proved in clinical trials to produce greater weight reduction than single-receptor approaches.
The weight-loss outcomes in pivotal trials were striking enough to prompt serious reconsideration of obesity as a purely behavioural or metabolic problem. In the SURMOUNT-1 trial, tirzepatide at its highest dose produced mean body weight reductions of 22.5% over 72 weeks in non-diabetic participants with obesity. The average adult of 100 kilograms loses 22 kilograms. These are figures previously achievable only through bariatric surgery.
Beyond Weight: The SELECT Trial Changed Everything
The inflection point in scientific understanding came with the publication of the SELECT trial in November 2023, followed by its full analysis in 2024 and longer-term follow-up data released through 2026.
SELECT was a cardiovascular outcomes trial: 17,604 adults with pre-existing cardiovascular disease and obesity but without diabetes, randomised to semaglutide 2.4mg weekly or placebo, followed for a median of 33 months. The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — the same hard clinical outcomes trials are powered to detect.
Semaglutide reduced the primary endpoint by 20% relative to placebo. This effect was independent of how much weight participants lost — suggesting that GLP-1 receptor agonism has direct cardiovascular protective effects beyond what weight reduction alone would predict. The magnitude of benefit was comparable to adding a statin to a patient who had never been treated with one.
The follow-up analyses published in 2025 and 2026 probed the mechanism. Reductions in systemic inflammation (measured by high-sensitivity C-reactive protein) were observed within weeks, before meaningful weight loss had occurred. This pointed toward direct anti-inflammatory effects on arterial walls and cardiac tissue — a finding that opened a new line of inquiry about what GLP-1 receptors are doing outside the gut and hypothalamus.
They are found, it turns out, throughout the body. In the kidneys, where GLP-1 agonism shows protective effects in chronic kidney disease. In the liver, where it ameliorates non-alcoholic steatohepatitis. In the lungs, where early signals suggest reduced exacerbations in sleep apnoea. And, most provocatively, in the brain.
The Addiction Finding Nobody Expected
In the early clinical trials, patients and clinicians noticed something anecdotal but consistent: people on GLP-1 medications reported reduced interest in alcohol. Some found cravings for cigarettes diminished. Others noted that compulsive behaviours — scrolling, overeating specific comfort foods, even gambling — felt less urgent.
These observations were dismissed as secondary to weight loss and the general wellbeing improvements that accompanied it. Then the mechanistic data began to arrive.
GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens — the core circuitry of dopaminergic reward. Animal studies published in Nature Neuroscience in 2024 demonstrated that semaglutide reduced self-administration of alcohol, cocaine, and fentanyl in rodent models. The animals did not become incapable of consuming these substances. They simply appeared to value them less. The wanting — the neurobiological pull that precedes consumption — was attenuated.
Human data followed. A retrospective study published in Nature Medicine in 2025, using insurance claims data from over 200,000 patients, found that individuals prescribed GLP-1 agonists for obesity had significantly lower rates of substance use disorder diagnoses and emergency presentations related to alcohol intoxication over the following two years compared to matched controls receiving other anti-obesity medications.
Several addiction medicine specialists have begun prescribing semaglutide off-label for alcohol use disorder and nicotine dependence. Phase 2 trials are now underway with primary addiction endpoints. The mechanism hypothesis is that GLP-1 agonism in the mesolimbic pathway reduces the salience of reward cues — not just food, but any stimulus that had previously acquired motivational weight through dopaminergic conditioning.
If this proves out in Phase 3 trials, it would represent a pharmacological approach to addiction disorders that operates through a completely different mechanism than anything currently approved — and would broaden the addressable market for GLP-1 drugs by orders of magnitude.
The Alzheimer's Signal
The most significant emerging finding — tentative, but supported by enough evidence to demand attention — concerns neurodegeneration.
GLP-1 receptors are expressed on microglia and astrocytes throughout the central nervous system. Neuroinflammation is increasingly understood as a critical driver of Alzheimer's disease progression, not merely a secondary consequence of amyloid accumulation. Several GLP-1 receptor agonists have shown neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, reducing neuroinflammation and improving cognitive performance in rodent studies since the early 2010s.
The EVOKE and EVOKE+ trials, which evaluated semaglutide in early Alzheimer's disease, completed enrollment in 2024 and are expected to report primary results in 2026 and 2027. Preliminary biomarker data from interim analyses, presented at the Alzheimer's Association International Conference in 2025, showed reductions in neuroinflammatory markers and signals consistent with slowed tau accumulation in the semaglutide arm.
These are exploratory findings in a trial not powered for cognitive outcomes. They do not constitute evidence of efficacy in Alzheimer's treatment. But they are consistent with the mechanistic story — that GLP-1 agonism reduces systemic and central nervous system inflammation through a pathway that is relevant across multiple disease contexts.
What This Means for Investors
The financial implications of a drug class with applications in obesity, cardiovascular disease, kidney disease, liver disease, addiction, and potentially neurodegeneration are difficult to overstate.
Novo Nordisk and Eli Lilly — the two incumbents with approved GLP-1 products — have undergone extraordinary market capitalisation expansion. Novo Nordisk briefly became the most valuable European company by market cap in 2024. By mid-2026, global GLP-1 drug revenues are tracking toward $80 to $90 billion annually, with projections from Goldman Sachs and Morgan Stanley suggesting $150 to $200 billion by 2030 as oral formulations reach market and manufacturing constraints ease.
The oral semaglutide story is significant. Injectable formulations present access and adherence barriers — needles, refrigeration, training. Rybelsus, the existing oral semaglutide for diabetes, showed modest weight-loss effects because of bioavailability constraints. Novo Nordisk's next-generation oral semaglutide formulations, combined with absorption enhancers, produced weight reductions approaching 15% in Phase 3 trials published in 2025 — closing much of the efficacy gap with injectable versions. Orforglipron, Eli Lilly's small-molecule oral GLP-1 agonist, showed comparable results in the ATTAIN trials.
An oral pill that achieves 12 to 15% weight reduction with once-daily dosing, at a cost per unit lower than injectables, would remove the primary remaining barriers to mass adoption. Analysts estimate this could expand the treated population from the current 10 to 12 million patients globally to 50 million or more within five years.
The broader pharmaceutical ecosystem is responding. Companies developing complementary drugs for muscle preservation — the loss of lean mass alongside fat is the primary clinical concern with GLP-1 agonists at scale — have attracted significant capital. Drugs targeting myostatin, activin receptors, and bimagrumab (which preserves or grows muscle while GLP-1 agonists drive fat loss) are in late-stage development at multiple companies. The combination approach — GLP-1 for fat reduction, anti-myostatin for muscle preservation — is increasingly discussed as the obesity treatment paradigm of the late 2020s.
The Concerns That Remain
The risk profile of GLP-1 agonists is not trivial. Gastrointestinal side effects — nausea, vomiting, gastroparesis — are common during dose escalation and cause discontinuation in a meaningful proportion of patients. The rate of muscle loss accompanying fat loss is approximately 25 to 40% of total weight lost in most trials — clinically significant over time, particularly in older adults for whom muscle mass is a longevity-critical resource.
Longer-term safety data is still accumulating. The question of thyroid C-cell tumours — which appeared in rodent studies at suprapharmacological doses — has not been resolved at the population level. Pancreatitis risk remains a subject of surveillance. Rare cases of non-arteritic anterior ischaemic optic neuropathy (a form of vision loss) have been reported in retrospective analyses, though causality remains unestablished.
The rebound problem is real. When patients discontinue GLP-1 agonists, the majority regain most of the lost weight within one to two years. This has complicated the clinical and economic framing: these may be drugs that require lifelong use to maintain their benefits, which creates questions about long-term safety, cost sustainability, and access equity that no current healthcare system has fully resolved.
The Frame That Makes Sense of It
The most useful way to think about GLP-1 agonists in 2026 is as the first broadly tolerated drugs that operate on the hedonic and inflammatory systems simultaneously — reducing both the metabolic dysfunction and the neurobiological pull that sustain obesity and related conditions.
Obesity was long categorised as a behavioural disorder amenable to willpower intervention. That framing was always scientifically thin — the neurobiological circuits governing appetite and reward are not amenable to voluntary override in most people, any more than blood pressure is amenable to voluntary reduction. GLP-1 agonists do not cure this. But they pharmacologically shift the set points that the brain defends, making behaviour change possible where it was previously almost impossible to sustain.
The full clinical picture will take another decade to resolve. What is clear already is that the drug class has crossed a threshold: the evidence base is too large, the mechanisms too well-characterised, and the outcomes too consistent to treat GLP-1 agonism as a transient trend. Something real is happening here. The question is how far it reaches.